Evaluation of effectiveness and safety of amlodipine/valsartan/hydrochlorothiazide single-pill combination therapy in hypertensive patients: an observational study
- PMID: 27536448
- PMCID: PMC4937637
- DOI: 10.3109/21556660.2014.884506
Evaluation of effectiveness and safety of amlodipine/valsartan/hydrochlorothiazide single-pill combination therapy in hypertensive patients: an observational study
Abstract
Objective: This study evaluated the effectiveness and safety of amlodipine/valsartan/hydrochlorothiazide (A + V + H) single-pill combination therapy in the treatment of hypertensive patients in daily practice.
Design and methods: This prospective, open-label, observational study, enroled adults for whom their physician considered treatment with the single pill combination as indicated. The observational period per patient was ∼3 months. Results were evaluated using basic descriptive statistical methods.
Main outcome: Data of 7132 patients were analyzed. At baseline, the mean blood pressure (BP) was 158.8 ± 17.7 mmHg (systolic, sBP) and 91.5 ± 10.7 mmHg (diastolic, dBP). The most common cardiovascular risk factors were positive family history, dyslipidemia, and diabetes mellitus. The most commonly used daily doses of A + V + H at study end were 5/160/12.5 mg (30.5%) or 10/160/12.5 mg (33.1%). At the last visit mean BP was 135.0 ± 11.8 mmHg (sBP) and 80.2 ± 7.3 mmHg (dBP). The mean BP reduction at last visit compared with baseline was -23.7 ± 17.5 mmHg (sBP) and -11.3 ± 10.6 mmHg (dBP); 43.5% of the patients reached normalization (BP <140/90 mmHg for non-diabetics or <130/80 mmHg for diabetics) and 71.3% reached therapeutic response (sBP <140 or ≥20 mmHg decrease vs baseline and dBP <90 or ≥10 mmHg decrease vs baseline in non-diabetic patients and sBP <130 mmHg or ≥20 mmHg decrease vs baseline and dBP <80 mmHg or ≥10 mmHg decrease vs baseline in patients with diabetes). Adverse events (AEs) were recorded in 2.3% of the patients, the most frequent being peripheral edema (0.6%) and dizziness (0.2%).
Conclusions: In daily practice, A + V + H single-pill treatment effectively lowered the average BP in patients with essential hypertension and was well tolerated.
Keywords: Amlodipine; Combination; Hydrochlorothiazide; Hypertension; Observational study; Triple therapy; Valsartan.
Figures


Similar articles
-
Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan.Ther Adv Cardiovasc Dis. 2014 Apr;8(2):45-55. doi: 10.1177/1753944714525496. Epub 2014 Feb 20. Ther Adv Cardiovasc Dis. 2014. PMID: 24562476
-
Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.Curr Med Res Opin. 2009 Feb;25(2):421-30. doi: 10.1185/03007990802656468. Curr Med Res Opin. 2009. PMID: 19192987 Clinical Trial.
-
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.Clin Ther. 2005 May;27(5):578-87. doi: 10.1016/j.clinthera.2005.05.006. Clin Ther. 2005. PMID: 15978306 Clinical Trial.
-
Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study.Curr Med Res Opin. 2014 Oct;30(10):1937-45. doi: 10.1185/03007995.2014.942415. Epub 2014 Jul 17. Curr Med Res Opin. 2014. PMID: 25007309
-
Efficacy and effectiveness of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide in hypertension: randomized controlled versus observational studies.Curr Med Res Opin. 2018 Mar;34(3):501-515. doi: 10.1080/03007995.2017.1412682. Epub 2018 Jan 22. Curr Med Res Opin. 2018. PMID: 29210288 Review.
References
-
- Hajjar I, Kotchen JM, Kotchen TA. Hypertension: trends in prevalence, incidence, and control. Annu Rev Public Health 2006;27:465-90 - PubMed
-
- Lawes CM, Vander HS, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-8 - PubMed
-
- Whitworth JA, World Health Organization, International Society of Hypertension Writing Group . 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-92 - PubMed
-
- Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-50 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources